3000 PEGASUS PARK DRIVE, DALLAS, TX
Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
2026 Annual Meeting Results; Stockholders Vote on Director Elections
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Reports Full-Year 2025 Financial Results and Provides Corporate Update
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Q1
FY 2025
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities